Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Pau d'Arco has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Lapachol and vitamin K share the naphthoquinone ring that the recycling enzyme recognises. High-dose lapachol has been described as antagonising vitamin K dependent clotting factor synthesis, and vitamin K is the counterweight. Anyone on a vitamin K antagonist is in exactly the wrong place for this combination and should be talking to whoever manages their anticoagulation.
Nattokinase has fibrinolytic activity and lapachol can interfere with clotting factor production. The two act at different points but push the same direction. Combining them raises bleeding risk without any evidence that the combination does anything useful.
Long-chain omega-3 fatty acids reduce platelet aggregation through changes in eicosanoid production. Stacking that with a naphthoquinone that can interfere with clotting factors compounds the effect. Worth flagging before any procedure with a bleeding risk.
Ginkgolides antagonise platelet-activating factor, and pau d'arco adds a separate route to impaired clotting. The two together carry more bleeding risk than either alone. This is an interaction to flag, not a pairing to build around.
Allicin-derived sulfur compounds inhibit platelet aggregation at supplement doses. Adding pau d'arco stacks a second mechanism affecting haemostasis on top. The combined effect deserves attention around surgery or dental work.
Ascorbate reduces quinones to hydroquinones, and the redox couple can either quench or accelerate cycling depending on the local oxygen and metal environment. Direction is not predictable from first principles for this pairing. Read it as an open question rather than as a benefit.
Lapachol is lipophilic and barely soluble in water. A lipid vehicle keeps far more of it in solution through the gut than an aqueous preparation does. That raises what gets absorbed, which cuts both ways given the dose-dependent toxicity.
Naphthoquinones are metabolised in the liver and redox-cycling compounds place a demand on hepatic glutathione. Silymarin is commonly added alongside herbs with that profile. The pairing is convention among formulators and has not been tested for this combination.
Nothing specific on file for Pau d'Arco. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 2 we read for Pau d'Arco. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.